|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: IER3 |
Gene summary for IER3 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | IER3 | Gene ID | 8870 |
| Gene name | immediate early response 3 | |
| Gene Alias | DIF-2 | |
| Cytomap | 6p21.33 | |
| Gene Type | protein-coding | GO ID | GO:0006915 | UniProtAcc | A0A1U9X7X2 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 8870 | IER3 | GSM4909281 | Human | Breast | IDC | 2.69e-24 | -7.91e-01 | 0.21 |
| 8870 | IER3 | GSM4909285 | Human | Breast | IDC | 2.45e-10 | -3.83e-01 | 0.21 |
| 8870 | IER3 | GSM4909286 | Human | Breast | IDC | 2.16e-53 | -1.09e+00 | 0.1081 |
| 8870 | IER3 | GSM4909287 | Human | Breast | IDC | 2.09e-06 | -5.07e-01 | 0.2057 |
| 8870 | IER3 | GSM4909290 | Human | Breast | IDC | 3.28e-08 | -5.47e-01 | 0.2096 |
| 8870 | IER3 | GSM4909291 | Human | Breast | IDC | 1.70e-06 | -6.04e-01 | 0.1753 |
| 8870 | IER3 | GSM4909294 | Human | Breast | IDC | 1.01e-23 | -7.67e-01 | 0.2022 |
| 8870 | IER3 | GSM4909296 | Human | Breast | IDC | 4.80e-19 | -6.09e-01 | 0.1524 |
| 8870 | IER3 | GSM4909297 | Human | Breast | IDC | 4.59e-09 | -2.42e-01 | 0.1517 |
| 8870 | IER3 | GSM4909298 | Human | Breast | IDC | 2.17e-11 | -5.38e-01 | 0.1551 |
| 8870 | IER3 | GSM4909302 | Human | Breast | IDC | 4.50e-30 | -9.36e-01 | 0.1545 |
| 8870 | IER3 | GSM4909304 | Human | Breast | IDC | 1.08e-08 | -5.41e-01 | 0.1636 |
| 8870 | IER3 | GSM4909306 | Human | Breast | IDC | 4.24e-04 | 2.93e-01 | 0.1564 |
| 8870 | IER3 | GSM4909308 | Human | Breast | IDC | 4.14e-03 | 2.70e-01 | 0.158 |
| 8870 | IER3 | GSM4909311 | Human | Breast | IDC | 1.46e-21 | -3.13e-01 | 0.1534 |
| 8870 | IER3 | GSM4909312 | Human | Breast | IDC | 4.68e-02 | -1.80e-01 | 0.1552 |
| 8870 | IER3 | GSM4909315 | Human | Breast | IDC | 1.02e-26 | -7.96e-01 | 0.21 |
| 8870 | IER3 | GSM4909316 | Human | Breast | IDC | 1.93e-13 | -1.02e+00 | 0.21 |
| 8870 | IER3 | GSM4909319 | Human | Breast | IDC | 7.51e-39 | 2.80e-01 | 0.1563 |
| 8870 | IER3 | GSM4909320 | Human | Breast | IDC | 1.67e-05 | -6.83e-01 | 0.1575 |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Breast |  | IDC: Invasive ductal carcinoma |
| DCIS: Ductal carcinoma in situ | ||
| Precancer(BRCA1-mut): Precancerous lesion from BRCA1 mutation carriers | ||
| Cervix |  | CC: Cervix cancer |
| HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions | ||
| N_HPV: HPV-infected normal cervix | ||
| Endometrium |  | AEH: Atypical endometrial hyperplasia |
| EEC: Endometrioid Cancer | ||
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| GC |  | CAG: Chronic atrophic gastritis |
| CAG with IM: Chronic atrophic gastritis with intestinal metaplasia | ||
| CSG: Chronic superficial gastritis | ||
| GC: Gastric cancer | ||
| SIM: Severe intestinal metaplasia | ||
| WIM: Wild intestinal metaplasia | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Lung |  | AAH: Atypical adenomatous hyperplasia |
| AIS: Adenocarcinoma in situ | ||
| IAC: Invasive lung adenocarcinoma | ||
| MIA: Minimally invasive adenocarcinoma | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Prostate |  | BPH: Benign Prostatic Hyperplasia |
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:20010208 | Breast | Precancer | regulation of response to DNA damage stimulus | 24/1080 | 219/18723 | 1.93e-03 | 1.87e-02 | 24 |
| GO:200102013 | Breast | IDC | regulation of response to DNA damage stimulus | 30/1434 | 219/18723 | 1.36e-03 | 1.40e-02 | 30 |
| GO:200102023 | Breast | DCIS | regulation of response to DNA damage stimulus | 30/1390 | 219/18723 | 8.32e-04 | 9.47e-03 | 30 |
| GO:20010209 | Cervix | CC | regulation of response to DNA damage stimulus | 46/2311 | 219/18723 | 1.92e-04 | 2.23e-03 | 46 |
| GO:190495115 | Endometrium | AEH | positive regulation of establishment of protein localization | 74/2100 | 319/18723 | 7.05e-10 | 6.51e-08 | 74 |
| GO:005122215 | Endometrium | AEH | positive regulation of protein transport | 66/2100 | 303/18723 | 7.79e-08 | 3.99e-06 | 66 |
| GO:00481939 | Endometrium | AEH | Golgi vesicle transport | 60/2100 | 296/18723 | 3.65e-06 | 9.79e-05 | 60 |
| GO:00068886 | Endometrium | AEH | endoplasmic reticulum to Golgi vesicle-mediated transport | 29/2100 | 130/18723 | 2.11e-04 | 2.59e-03 | 29 |
| GO:00507087 | Endometrium | AEH | regulation of protein secretion | 49/2100 | 268/18723 | 3.83e-04 | 4.12e-03 | 49 |
| GO:00507149 | Endometrium | AEH | positive regulation of protein secretion | 28/2100 | 137/18723 | 1.17e-03 | 1.01e-02 | 28 |
| GO:200102010 | Endometrium | AEH | regulation of response to DNA damage stimulus | 40/2100 | 219/18723 | 1.28e-03 | 1.09e-02 | 40 |
| GO:0035265 | Endometrium | AEH | organ growth | 33/2100 | 178/18723 | 2.53e-03 | 1.87e-02 | 33 |
| GO:00716927 | Endometrium | AEH | protein localization to extracellular region | 58/2100 | 368/18723 | 4.72e-03 | 3.00e-02 | 58 |
| GO:00093068 | Endometrium | AEH | protein secretion | 56/2100 | 359/18723 | 6.71e-03 | 3.94e-02 | 56 |
| GO:00355928 | Endometrium | AEH | establishment of protein localization to extracellular region | 56/2100 | 360/18723 | 7.10e-03 | 4.09e-02 | 56 |
| GO:190495116 | Endometrium | EEC | positive regulation of establishment of protein localization | 74/2168 | 319/18723 | 2.90e-09 | 2.10e-07 | 74 |
| GO:005122216 | Endometrium | EEC | positive regulation of protein transport | 66/2168 | 303/18723 | 2.55e-07 | 1.09e-05 | 66 |
| GO:004819313 | Endometrium | EEC | Golgi vesicle transport | 60/2168 | 296/18723 | 9.91e-06 | 2.17e-04 | 60 |
| GO:000688812 | Endometrium | EEC | endoplasmic reticulum to Golgi vesicle-mediated transport | 29/2168 | 130/18723 | 3.63e-04 | 3.95e-03 | 29 |
| GO:005070813 | Endometrium | EEC | regulation of protein secretion | 50/2168 | 268/18723 | 4.33e-04 | 4.51e-03 | 50 |
| Page: 1 2 3 4 5 6 7 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| IER3 | SNV | Missense_Mutation | c.371C>T | p.Pro124Leu | p.P124L | P46695 | protein_coding | deleterious(0.05) | benign(0.056) | TCGA-MU-A51Y-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD | |
| IER3 | SNV | Missense_Mutation | c.7C>T | p.His3Tyr | p.H3Y | P46695 | protein_coding | tolerated(0.36) | benign(0.442) | TCGA-DD-A73D-01 | Liver | liver hepatocellular carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | |
| IER3 | SNV | Missense_Mutation | c.194N>C | p.Val65Ala | p.V65A | P46695 | protein_coding | deleterious(0.01) | probably_damaging(0.994) | TCGA-CG-5721-01 | Stomach | stomach adenocarcinoma | Male | <65 | III/IV | Unknown | Unknown | SD |
| Page: 1 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |